ONCIN — Oncoinvent ASA Share News
0.000.00%
Last trade - 00:00- NOK305.43m
- NOK200.69m
- NOK28.07m
Brief: Bergenbio: Data From Phase I/II Bemcentinib/Erlotinib Combination Trial
Brief: Bergenbio Q1 Operating Loss Widens To NOK 83.4 Mln
Brief: BerGenBio Announces Top Line Data From Phase II Trial Assessing Bemcentinib In Hospitalised COVID-19 Patients
Brief: Bergenbio: Update From Investigational Phase II Trials Assessing Bemcentinib In Hospitalised COVID-19 Patients
Brief: Bergenbio Announces Stopped Recruitment To The Bemcentinib Arm In UK Accord Covid Platform Trial
Brief: Bergenbio Says Effect Of Bemcentinib Demonstrated Potent Antiviral Effects In Preclinical SARS-CoV-2 And Other Coronavirus Models
Brief: Bergenbio Q4 Operating Loss Widens To NOK 71.8 Million
Brief: Bergenbio: Second Data Monitoring Committee Recommends Continuation Of BGBC020 Trial
Brief: Bergenbio: Update From Ongoing Phase II Bemcentinib Combination Study In Refractory NSCLC At WCLC 2020
Brief: Bergenbio Says Bemcentinib Shows Promising Clinical Activity In Lung Cancer
Brief: Bergenbio Q3 Loss After Tax Widens To NOK 67.3 Million
Brief: BerGenBio Presents Phase II Bemcentinib Combination Study In NSCLC At Annual SITC Meeting
Brief: Bergenbio Presents Data On Anti-Axl Antibody Tilvestamab At 32 Ena
Brief: Bergenbio Receives Regulatory Approval To Commence Phase II Trial Of Bemcentinib For COVID-19 In India
Brief: Bergenbio: ACCORD Clinical Study Assessing Bemcentinib In COVID-19 Patients To Recommence In UK
Brief: Bergenbio Gets Approval For COVID-19 South Africa Trial
Brief: Bergenbio Gets Approval To Commence Phase II Trial Of Bemcentinib For COVID-19 In South Africa
Brief: Bergenbio's Bemcentinib Meets Efficacy Endpoint In Bergamo Phase II Trial
Brief: BerGenBio Q2 Operating Loss For Quarter Widens To NOK 64.7 Mln